Thrombocytopenia is a possible side effect of routinely administered medical agents. Abciximab is one of the three potent intravenous glycoprotein IIb/IIIa receptor inhibitors (along with eptifibatide and tirofiban) that have shown significant positive outcomes when used in patients with intracoronary thrombus. The use of abciximab was associated with the risk of thrombocytopenia. In this case, the development of thrombocytopenia and treatment management were reported after the use of abciximab.
Primary Language | English |
---|---|
Subjects | Health Care Administration |
Journal Section | Case Report |
Authors | |
Early Pub Date | March 18, 2022 |
Publication Date | March 18, 2022 |
Submission Date | January 28, 2022 |
Acceptance Date | March 17, 2022 |
Published in Issue | Year 2022 Volume: 39 Issue: 2 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.